RhumbLine Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.14M | Buy |
124,125
+20,718
| +20% | +$515K | ﹤0.01% | 1563 |
|
|
2026
Q1 | $2.17M | Buy |
103,407
+1,581
| +2% | +$35.6K | ﹤0.01% | 1809 |
|
|
2025
Q4 | $2.34M | Sell |
101,826
-3,905
| -4% | -$128K | ﹤0.01% | 1785 |
|
|
2025
Q3 | $3.18M | Buy |
105,731
+2,105
| +2% | +$63.1K | ﹤0.01% | 1652 |
|
|
2025
Q2 | $3.77M | Sell |
103,626
-1,167
| -1% | -$42.1K | ﹤0.01% | 1562 |
|
|
2025
Q1 | $3.79M | Buy |
104,793
+195
| +0.2% | +$8.11K | ﹤0.01% | 1487 |
|
|
2024
Q4 | $4.4M | Sell |
104,598
-5,694
| -5% | -$282K | ﹤0.01% | 1487 |
|
|
2024
Q3 | $6.13M | Buy |
110,292
+13,582
| +14% | +$692K | 0.01% | 1318 |
|
|
2024
Q2 | $3.97M | Buy |
96,710
+5,047
| +6% | +$215K | ﹤0.01% | 1515 |
|
|
2024
Q1 | $4.28M | Sell |
91,663
-9,002
| -9% | -$425K | ﹤0.01% | 1491 |
|
|
2023
Q4 | $4.81M | Buy |
100,665
+8,050
| +9% | +$312K | 0.01% | 1437 |
|
|
2023
Q3 | $3.3M | Sell |
92,615
-422
| -0.5% | -$16.7K | ﹤0.01% | 1583 |
|
|
2023
Q2 | $4.29M | Buy |
93,037
+12,406
| +15% | +$575K | ﹤0.01% | 1470 |
|
|
2023
Q1 | $3.23M | Buy |
80,631
+4,678
| +6% | +$201K | ﹤0.01% | 1567 |
|
|
2022
Q4 | $3.52M | Buy |
75,953
+2,662
| +4% | +$105K | ﹤0.01% | 1492 |
|
|
2022
Q3 | $3.04M | Buy |
73,291
+1,897
| +3% | +$97.5K | ﹤0.01% | 1536 |
|
|
2022
Q2 | $4.26M | Buy |
71,394
+4,840
| +7% | +$298K | 0.01% | 1334 |
|
|
2022
Q1 | $4.83M | Sell |
66,554
-4,092
| -6% | -$285K | 0.01% | 1338 |
|
|
2021
Q4 | $5.94M | Buy |
70,646
+436
| +0.6% | +$35.5K | 0.01% | 1266 |
|
|
2021
Q3 | $6.33M | Sell |
70,210
-1,839
| -3% | -$166K | 0.01% | 1214 |
|
|
2021
Q2 | $6.87M | Sell |
72,049
-5,778
| -7% | -$602K | 0.01% | 1243 |
|
|
2021
Q1 | $8.86M | Sell |
77,827
-7,376
| -9% | -$1M | 0.01% | 1067 |
|
|
2020
Q4 | $11.8M | Buy |
85,203
+7,818
| +10% | +$927K | 0.02% | 823 |
|
|
2020
Q3 | $6.36M | Sell |
77,385
-15,320
| -17% | -$1.27M | 0.01% | 1012 |
|
|
2020
Q2 | $7.25M | Buy |
92,705
+7,197
| +8% | +$476K | 0.01% | 952 |
|
|
2020
Q1 | $3.8M | Buy |
85,508
+1,458
| +2% | +$75.7K | 0.01% | 1195 |
|
|
2019
Q4 | $3.59M | Buy |
84,050
+3,419
| +4% | +$141K | 0.01% | 1459 |
|
|
2019
Q3 | $3.45M | Sell |
80,631
-1,364
| -2% | -$74.1K | 0.01% | 1400 |
|
|
2019
Q2 | $5.21M | Buy |
81,995
+7,178
| +10% | +$457K | 0.01% | 1172 |
|
|
2019
Q1 | $5.19M | Buy |
74,817
+9,256
| +14% | +$529K | 0.01% | 1155 |
|
|
2018
Q4 | $2.85M | Buy |
65,561
+23,041
| +54% | +$1.26M | 0.01% | 1439 |
|
|
2018
Q3 | $3.25M | Sell |
42,520
-2,454
| -5% | -$200K | 0.01% | 1385 |
|
|
2018
Q2 | $3.46M | Buy |
44,974
+3,891
| +9% | +$251K | 0.01% | 1351 |
|
|
2018
Q1 | $2.1M | Buy |
41,083
+2,497
| +6% | +$126K | ﹤0.01% | 1586 |
|
|
2017
Q4 | $1.79M | Sell |
38,586
-7,707
| -17% | -$378K | ﹤0.01% | 1686 |
|
|
2017
Q3 | $2.47M | Buy |
46,293
+889
| +2% | +$52.7K | 0.01% | 1480 |
|
|
2017
Q2 | $2.82M | Sell |
45,404
-502
| -1% | -$30.2K | 0.01% | 1353 |
|
|
2017
Q1 | $3.11M | Buy |
45,906
+4,278
| +10% | +$326K | 0.01% | 1300 |
|
|
2016
Q4 | $2.93M | Buy |
41,628
+1,183
| +3% | +$83.9K | 0.01% | 1225 |
|
|
2016
Q3 | $2.87M | Buy |
40,445
+1,224
| +3% | +$78.1K | 0.01% | 1181 |
|
|
2016
Q2 | $1.92M | Sell |
39,221
-65
| -0.2% | -$4.21K | 0.01% | 1366 |
|
|
2016
Q1 | $2.49M | Buy |
39,286
+170
| +0.4% | +$11.1K | 0.01% | 1222 |
|
|
2015
Q4 | $4.39M | Buy |
39,116
+3,266
| +9% | +$327K | 0.01% | 885 |
|
|
2015
Q3 | $3.45M | Buy |
35,850
+5,076
| +16% | +$581K | 0.01% | 1007 |
|
|
2015
Q2 | $3.15M | Buy |
30,774
+24,290
| +375% | +$1.89M | 0.01% | 1119 |
|
|
2015
Q1 | $403K | Buy |
6,484
+1,225
| +23% | +$68K | ﹤0.01% | 2432 |
|
|
2014
Q4 | $231K | Hold |
5,259
| – | – | ﹤0.01% | 2726 |
|
|
2014
Q3 | $298K | Buy |
5,259
+215
| +4% | +$10.8K | ﹤0.01% | 2521 |
|
|
2014
Q2 | $226K | Buy |
+5,044
| New | +$208K | ﹤0.01% | 2765 |
|
Other funds holding RARE
RI
FCM
RhumbLine Advisers's RARE Position: Q2 2026 in Review
RhumbLine Advisers increased its Ultragenyx Pharmaceutical (RARE) stake by 20% in Q2 2026, buying an estimated $515K and bringing the position to 124,125 shares worth $4.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1563.
RhumbLine Advisers first reported a position in RARE in Q2 2014 and has held it in 49 quarters since. The position peaked at $11.8M in Q4 2020. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- RhumbLine Advisers held 124,125 shares of Ultragenyx Pharmaceutical worth $4.14M as of Q2 2026.
- RhumbLine Advisers bought 20,718 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $515K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1563 holding.
- RhumbLine Advisers first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and has held it in 49 quarters since.
- RhumbLine Advisers's Ultragenyx Pharmaceutical position peaked at $11.8M in Q4 2020.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.